New SWITCH trial registered pitting apixaban against warfarin in HeartMate 3 patients

Two registry items are active this week tied to cardiovascular device trials.

• A new trial called SWITCH (NCT07471139) is comparing apixaban to vitamin K antagonists in patients with HeartMate 3 left ventricular assist devices. The study is a prospective, randomized, controlled, non-inferiority trial evaluating apixaban versus vitamin K antagonists in HM3 patients more than 3 months post-implant.¹ It is sponsored by Columbia University, with an actual start date of 2026-10-15 and an estimated enrollment of 460 participants,¹ and is listed as recruiting at a single site, Columbia University Irving Medical Center.
• The ACHILLES-HF trial (NCT07758023) is testing whether early transcatheter edge-to-edge repair (TEER) in patients with heart failure and reduced ejection fraction and secondary mitral regurgitation leads to faster guideline-directed therapy up-titration and better outcomes. It is sponsored by University Medical Center Mainz, with Abbott as a collaborator,² and is listed as recruiting with an estimated enrollment of 520 participants,² with its record last updated on 2026-11-02.